Immunogenicity from COVID-19 infection might not different from the immunogenicity of booster vaccination. COVID-19
Conditions
Interventions
Infected with COVID-19 after vaccination with Sinovac for 2 doses,Received a booster dose (AstraZeneca) after had receiveded vaccination with Sinovac for 2 doses
Prevention,Prevention
COVID-19 infected group,Booster group
Sponsors
Ratchadapiseksompotch Research Fund
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. 18-60 years old 2. Can comply with the trial 3. Either had been infected with COVID-19 after vaccination or had a booster dose of vaccination
Exclusion criteria
Exclusion criteria: 1. Received any other vaccines within 4 months prior 2. Received blood or blood product or immunoglobulin within 3 months 3. In a high-level immunosuppression stage 4. Received monoclonal antibody, JAK inhibitor or convalescent plasma for COVID-19
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seroconversion rate by neutralizing antibody 3 and 6 months after infection or booster dose vaccination cPass SARS-CoV-2 Neutralization Antibody Detection Kit GenScript | — |
Secondary
| Measure | Time frame |
|---|---|
| Seroconversion rate by SARS-CoV2 antibody 3 and 6 months after infection or booster dose vaccination Enzyme-Linked Immunosorbent Assay (ELISA),Immunogenicity to variant strain 3 and 6 months after infection or booster dose vaccination Neutralization Antibody | — |
Countries
Thailand
Contacts
Public ContactVaralee Terbsiri
Faculty of Medicine, Chulalongkorn University
Outcome results
None listed